The Burr distribution as a model for the delay between key events in an individual's infection history

Nyall Jamieson^{1*}, Christiana Charalambous¹, David M. Schultz², Ian Hall¹

1 Department of Mathematics, University of Manchester, Manchester, United Kingdom
2 Centre for Atmospheric Sciences, Department of Earth and Environmental Sciences, and Centre for Crisis Studies and Mitigation, University of Manchester, Manchester, United Kingdom

* nyall.jamieson@postgrad.manchester.ac.uk

Abstract

Understanding the temporal relationship between key events in an individual's infection history is crucial for disease control. Delay data between events, such as infection and symptom onset times, is doubly censored because the exact time at which these key events occur is generally unknown. Current mathematical models for delay distributions rely solely on heuristic justifications for their applicability. Here, we derive a new model for delay distributions, specifically for incubation periods, motivated by bacterial-growth dynamics that lead to the Burr family of distributions being a valid modelling choice. We also incorporate methods within these models to account for the doubly censored data. Our approach provides biological justification in the derivation of our delay distribution model, the results of fitting to data highlighting the superiority of the Burr model compared to currently used models in the literature. Our results indicate that the derived Burr distribution is 13 times more likely to be a better-performing model to incubation-period data than currently used methods. Further, we show that incorporating methods for handling the censoring issue results in the mean of the underlying continuous incubation-period model being reduced by a whole day, compared to the mean obtained under alternative modelling techniques in the literature.

Author summary

In public health, it is important to know key temporal properties of diseases (such as how long someone is ill for or infectious for). Mathematical characterisation of properties requires information about patients' infection histories, such as the number of days between infection and symptom onset, for example. These methods provide useful insights, such as how their infectiousness varies over time since they were infected. However, two key issues arise with these approaches. First, these methods do not have strong arguments for the validity of their usage. Second, the data typically used is provided as a rounded number of days between key events, as opposed to the exact period of time. We address both these issues by developing a new mathematical model to describe the important properties of the infection process of various diseases based on strong biological justification, and further incorporating methods within the

mathematical model which consider infection and symptom onset to occur at any point within an interval, as opposed to an exact time. Our approach provides more preferable results, based on AIC, than existing approaches, enhancing the understanding of properties of diseases such as Legionnaires' disease.

Introduction

In epidemiology, the temporal relationship between key events in an individual's infection history is important to understand. For example, a disease that has a long delay from infection to onset of infectiousness may be amenable to contact tracing, and the relationship between these two events can be important for disease control [1, 2]. Often these events are a simplification of a continuous process (i.e., infectivity may not start or end at specific times but instead increase and then decrease over time). For diseases such as Legionnaires' disease, which spread via airborne dispersion from environmental sources (rather than person-to-person contact), characterisation of the incubation period is critical for source identification (or reverse epidemiology).

Here, we consider the time from infection to symptom onset. The relationship 11 between viral or bacterial load in one's body and onset of symptoms can be difficult to 12 describe. In brief, the presence of a virus or bacteria within an individual results in an 13 inflammatory immune response that leads to an observable response of symptoms. An 14 exact mathematical model accurately describing the infection process is not feasible to 15 develop due to the large number of different cytokines and cell interactions involved in the immune response, as well as a lack of a clear understanding of how the 17 pro-inflammatory cytokines relate to the appearance of symptoms and a lack of data to 18 parameterise each specific process in the immune response. Previous models for the incubation period provide parsimonious simplifications of the infection process, and include in-host models (often assuming symptom onset is proportional to bacterial 21 load [3]), through to simpler probability models (justified on model parsimony or 22 computational capacity). In the latter case, popular distributions include the gamma, 23 log-normal and Weibull distributions [4–6]. 24

The validity of these distributions has not been explored, and application is based 25 solely on heuristic justification. The arguments for common distributions can be

10

16

> described as follows. The gamma distribution is the sum of n exponentially distributed 27 random events, and so fitting to data can help inform the structure of compartmental models [7]. The log-normal distribution is a skewed distribution often applied to 29 biological processes in which the process mean time is relatively low, but its variance is large and results from taking the exponential of a series of normally distributed events. 31 Finally, the Weibull distribution is a classic reliability-theory distribution where the hazard of an event occurring is strictly monotonic over time. 33

> To illustrate the heuristic justification of distributions, we consider Legionnaires' disease and the statistical analysis that has been conducted in the literature for studying the incubation period. In this case, several papers have used a range of days (2–10) prior to symptom onset and consider all days in this period as a potential infection date [8–14]. Alternatively, others have assumed a median incubation period of either five days [15] or seven days [16], with infection dates obtained by subtracting the median from the symptom onset date. Another common approach is to consider a gamma-distributed incubation period [17]. All papers that take this approach have followed the ideas and method proposed in [4] using a gamma distribution to describe 42 an outbreak in Melbourne [18].

> One issue arising is that incubation-period data is given as an integer number of 11 days, implying that each case becomes infected at the same moment from the exposure, and that symptoms develop in an integer amount of days. To illustrate this issue, take two cases in which symptom onset occurs the day after infection. The individual could 47 have been infected at 11:59pm and became symptomatic at 00:01am the next day, or alternatively they could have been infected at 00:01am and became symptomatic at 11:59pm the next day. These two scenarios are 2 minutes and 1 day, 23 hours, 58 minutes long, respectively, but they both correspond to one integer day in the dataset. 51 These simplifications give a lower resolution of the time delay between these events due 52 to lack of knowledge of the exact infection and symptom onset times. Essentially, 53 continuous distributions are being fitted to discretized versions of continuous data, and 54 the result is interval data with censored start and end times.

> This type of discretized data is commonly used for analysis without consideration for the censoring issue. Using standard probability distributions, as well as censored 57 incubation-period data in statistical analysis, is likely to produce biased inference. Using

37

40

> incubation-period data expressed as an integer number of days will likely lead to a false understanding of delays between key events for specific diseases, such as the incubation period, and produce incorrect conclusions. A model describing the incubation period of Legionnaires' disease has been built with this type of data [4], but the model is flawed and can be improved upon by accounting for the issues mentioned above. There are various ways to handle the censoring issue, which we discuss in the next section.

> In this paper, a new model for incubation periods is derived with potentially stronger justification for its validity than methods currently used in the literature. We apply our new model to a variety of diseases to provide statistically significant improvements compared to currently accepted and used models. We also apply techniques that remove the bias from fitting models to censored data and allow for reliable model-fitting, providing a new understanding of the incubation periods of various diseases. We apply these methods to anthrax, salmonellosis and campylobacteriosis, as well as taking a specific focus on Legionnaires' disease to respect to respect the typical kind of improvement achievable with these methods. For the successful models, we develop some distribution theory, calculating their moments and quantile functions, which can be found in S1 Appendix in the Supplementary Material.

Materials and methods

In this section, we develop methods for handling both of the problems discussed in the 77 introduction. First, we adapt the methods developed in [19] for use on incubation-period data in order to account for its censored nature. Second, we consider 79 a probabilistic approach to develop a new model for incubation periods of diseases. We assume exponential growth of bacteria early after infection, as well as a further 81 assumption of the probability of symptom onset being proportional to the bacterial load within an individual until saturating once some load has been reached. Third, we 83 discuss the methods for analysing our fitted models and how we determine which model performs better, so that we can conclude whether or not our developed model offers more reliable results than using methods currently developed in the literature. Finally, we introduce the data used for incubation-period analysis and discuss the reasons why 87 this data is considered censored. 88

Doubly interval-censored modelling

Methods for handling censored data in epidemiological studies have been proposed in the literature to develop discrete analogues of continuous distributions that preserve properties of their continuous counterparts [20]. However, most of these methods are either too simple, do not result in valid probability mass functions, or assume that infection occurs exactly at midnight.

The exact time at which symptoms occur in an individual can not be determined based on when they reported their illness to authorities. Similarly, the exact time at which an individual becomes infected is also difficult to ascertain. We need a method for handling the fact that these times are unknown (i.e., to account for the uncertainty 98 within a model), so that analysis of any subsequent models is reliable. To consider 99 doubly censored data, a natural approach is to forget the assumption that the exact 100 infection and symptom onset times are known and introduce a time period in which 101 these two events may occur, with a probability distribution for the occurrence within 102 this period [19]. The method proposed in [19], which considers doubly interval-censored 103 (DI) data, is described as follows. 104

Define T and S to be the time of infection and symptom onset respectively (with t 105 and s being realisations of these random variables respectively), and Z = S - T as the 106 incubation period of the infection. Consider two intervals where T and S could lie 107 within because the exact times of T and S are not known. In other words, let 108 $T \in (T_L, T_R)$ and $S \in (S_L, S_R)$. The incubation period Z is given as a random variable 109 with p.d.f. f(s-t) (Fig. 1). 110

Fig 1. Diagram visualising the doubly interval-censoring method [19], highlighting ¹¹¹ the data typically observed, but accounting for the fact that infection and symptom ¹¹² onset times are not observed exactly and intervals of possible times must be considered. ¹¹³



The p.d.f. of T is defined as $f_T(t)$ and the p.d.f. of S is defined as $f_S(s)$. The time at which a person becomes infected and the time taken from infection to symptom onset

89

٥л

are independent, which leads to $f_S(s \mid t) = f(s-t \mid t) = f(s-t)$. Finally, define the joint p.d.f. of T and S as

$$p(t,s) = p(t)p(s \mid t) = f_T(t)f_S(s \mid t) = f_T(t)f(s-t).$$

From this, the likelihood for a doubly interval-censored observation x is derived.

$$L(x) = \int_{T_L}^{T_R} \int_{S_L}^{S_R} f_T(t) f(s-t) \, ds \, dt.$$

To implement methods found in [19] to incubation-period data, the following approach 119 is taken. Because the data is rounded to the nearest day, a natural assumption is that 120 $T_L = 0$ and $T_R = 1$, so infection occurs at any point on the infection date. Defining x to 121 be the number of days from exposure to symptom onset, set $S_R = x$ and $S_L = x - 1$, so 122 that the symptoms develop at some point on the stated date of symptom onset. There 123 is not much evidence to indicate what distribution $f_T(t)$ might be, so a reasonable 124 assumption would be to let $f_T(t)$ be uniform (i.e., $f_T(t) = 1$ on $t \in (0, 1)$, 0 otherwise). 125 Other options could be to permit a lower chance during nighttime or a higher chance 126 when people are outdoors, but these will depend on specific release scenarios and are 127 not likely particularly identifiable in data. As f(s-t) is the p.d.f. of the incubation 128 period, the log-likelihood is calculated as follows: 129

$$\ell(\mathbf{X}) = \sum_{j=1}^{n} \log\left[\int_{0}^{1} \int_{x_{j}-1}^{x_{j}} f(s-t) \, ds \, dt\right] = \sum_{j=1}^{n} \log\left[\int_{x_{j}-1}^{x_{j}} F(u) - F(u-1) \, du\right].$$
(1)

In the next section, we develop various distributions to describe the incubation period, 130 and later fit the doubly interval-censored model to these distributions, to determine 131 which one provides the most optimal fit. 132

Derivation of the incubation period model

133

Incubation period data describes the cases who become symptomatic. Given the knowledge that all individuals in the data will become symptomatic, this section discusses different mathematical models for the occurrence of symptoms onset within a population. We explore how the results for these different methods link and we develop

a new model for incubation periods, by starting from a probabilistic approach of symptom onset occurrence.

A probability-based approach

A mathematical model can be built considering probabilities of symptom onset 141 occurrence. Define N(t) as the population of individuals who are infected, but are not 142 yet symptomatic at time t, and Q(t) as the population of individuals who are 143 symptomatic at time t with $N(0) = N_0$ and Q(0) = 0 and $Q(t) + N(t) = N_0$, $\forall t \in \mathbb{R}^+$. 144 Next, assume that there is a probability p(t) that a not-vet-symptomatic individual will 145 start to experience symptoms at a point in time t, then 1-p(t) will be the probability 146 that the individual will remain asymptomatic. Hence $(1-p(t))^{N(t)}$ is the probability 147 that nobody who is not-vet-symptomatic will start experiencing symptoms at this point 148 in time, and $(1-p(t))^{N(t)\delta t}$ is the probability that nobody new will experience 149 symptoms in a time increment δt . Following this, define $\delta Q(t) = 1 - (1 - p(t))^{N(t)\delta t}$ to 150 be the probability that there is at least one individual who starts to experience new 151 symptoms in time increment δt . By writing $\mu(t) = -\log(1-p(t))$, the probability of any 152 new symptom onset appearance can be written as $\delta Q(t) = 1 - e^{-\mu(t)N(t)\delta t}$. Using a 153 Taylor expansion on the exponential term, dividing by δt , and taking the limit $\delta t \to 0$ 154 changes this probability to a rate as follows: 155

$$\frac{dQ(t)}{dt} = \mu(t)N(t) = \mu(t)(N_0 - Q(t)).$$
(2)

This approach leads to a separable ordinary differential equation analogous to the cumulative distribution of the exponential distribution with a time-varying rate parameter.

It can be deduced that $F(t) = 1 - \exp(-\int_0^t \mu(\tau) d\tau)$ and that $\int_0^t \mu(\tau) d\tau$ is the accumulated hazard. Hence the rate of symptom onset, $\mu(t)$, is the hazard function of an individual becoming symptomatic. Therefore, the hazard of an individual becoming symptomatic at a point in time is equal to the rate of symptom onset at that time. The scenario discussed here can be considered from an inhomogeneous Poisson-process perspective, and the results of the hazard are identical to the inhomogeneous exponentially distributed model. It can be noted here that if $\mu(t)$ is constant that this

156

157

158

138

139

> would lead to the exponential distribution and if $\mu(t) \propto t^a$ for some constant *a* this would suggest the incubation period is a Weibull distributed random variable. The gamma distribution arises by assuming the incubation period is the sum of a number of stages of constant length μ .

> However, symptom onset is likely proportional to bacterial load at low loads (i.e., 170 the early stages of infection) before saturating at large loads. The bacterial population 171 early after infection will be approximately some exponential function of time [3, 21, 22]. 172 Therefore, the left tail of the c.d.f. of the incubation-period distribution is given by 173 some function $e^{G_1(t)}$, whilst in the later stage, the c.d.f. should tend to 1 exponentially 174 given by a function $G_2(t)$, as is the case of the hazard function above. Mathematically, 175 with a median T, and considering the case where $G(t) = G_1(t) = G_2(t)$, an equation for 176 the c.d.f. that satisfies these conditions is given as follows: 177

$$\frac{dF(t)}{dt} = F(t)(1 - F(t))g(t),$$
(3)

where $G(t) = \int_0^t g(s) \, ds$ for some function g(s). The ODE that arises in (3) defines the Burr family of distributions and is discussed in further detail in the next section.

Burr distribution

A Burr distribution is a distribution whose c.d.f., F(t),

$$F(t) = \frac{e^{G(t)}}{1 + e^{G(t)}} = \frac{1}{1 + e^{-G(t)}}$$
(4)

is the solution of (3). Theoretically, there are no constraints on G(t) in (4). Twelve main distributions within the Burr family have been characterized [23], named as Burr type I, Burr type II, up-to Burr type XII, but we only consider Burr distributions defined over a domain of $(0, \infty)$.

Some delay distributions arising in epidemiology do permit negative values. For example, the time from symptom onset in infector to symptom onset in infectee could be negative. In this paper we limit consideration to strictly positive cases. A negative incubation period is not possible, nor is a fixed upper limit constraint expected. The only biologically feasible distributions are types III, X and XII. The type III

180

> distribution could be derived from the flexible generalized gamma distribution with the scale parameter following an inverse Weibull distribution [24]. Similarly, type XII could be derived from the Weibull distribution where the scale parameter follows an inverse generalized gamma distribution [24].

> The Burr distributions and the gamma distribution have parameters which share the 195 same symbols for notational simplicity, although they have different interpretations and 196 their fitted estimates can not be directly compared. To avoid confusion, we provide a 197 subscript for each parameter to clarify which distribution this parameter corresponds to 198 (i.e., α_{III} for the α parameter in the type III Burr model) in the text but drop this in 199 tables and figures for brevity. Further, we note that the types III, X and XII used in 200 this research are a generalization of types III, X and XII Burr distributions used in the 201 literature [23], where the time variable is scaled by an additional parameter. Type X is 202 defined with two variables that provide models as parsimonious as the three previously 203 trialled: gamma, log-normal, and Weibull. Further, both type III and XII have a scale 204 parameter $\gamma_{III,XII}$ and two shape parameters $\alpha_{III,XII}$ and $\beta_{III,XII}$. 205

General derived Burr distribution

In (3) g(t) has a physical interpretation; the function tends to the rate of symptom onset, 207 $\mu(t)$, in individuals at a time t as t increases. Given $F(t) = (1 + e^{-G(t)})^{-1}$, in general, 208 then $G(t) \to t/\beta_D$ (or $g(t) \to 1/\beta_D$) for some constant β_D as $t \to \infty$ on the basis that 209 relatively long incubation periods are memory-less Markovian random variables. In 210 principle, F(0) = 0, so $G(t) \to -\infty$ for $t \to 0$ (or G(0) is very large if not actually 211 infinite). Taking the above into account, we propose $g(t) = 1/\beta_D + \alpha_D/t$, and as such 212 $G(t) = t/\beta_D + \alpha_D \log(t) + C$, where C is a constant of integration. We define T_D as the 213 median, which satisfies $G(T_D) = 0$. Hence, $C = -T_D/\beta_D - \alpha_D \log(T_D)$ and thus 214

$$G(t) = \frac{t - T_D}{\beta_D} + \alpha_D \log\left(\frac{t}{T_D}\right).$$

Equations for the c.d.f. and p.d.f. for the derived Burr, as well as the gamma and other Burr distributions, are given in Table 1. As discussed, T_D is the median of the distribution. The reciprocal of β_D is the eventual Markovian rate of symptom onset in individuals for $t \gg T_D$. Additionally, there are two details worth noting when analysing 218

> the physical interpretation of α_D . First, α_D is an exponent of t controlling the growth of probability, as $F(t) \approx (t/T_D)^{\alpha_D} e^{(t-T_D)/\beta_D}$ for $t \ll T_D$. Second, the general derived Burr distribution approaches the exponential distribution for $t \gg T_D$. The rate at which the derived Burr approaches the exponential distribution increases for decreasing α_D . Therefore, the parameter α_D can be interpreted as a parameter that limits the rate at which the symptom onset process in an individual becomes Markovian. Finally, all parameters must be strictly greater than zero.

Table 1. The Burr distributions valid over $(0, \infty)$ and previously trialled226distributions [4] with their corresponding p.d.f and c.d.f., as well as the parameters in227each model.228

Distribution	p.d.f.	c.d.f.	Parameter Range
Gamma	$rac{eta^{-lpha}}{\Gamma(lpha)}t^{lpha-1}e^{-rac{t}{eta}}$	$rac{1}{\Gamma(lpha)}\gamma(lpha,eta t)$	$\alpha,\beta>0$
Log-normal	$\frac{1}{t\sigma\sqrt{2\pi}}e^{-\frac{(\log(t)-\mu)^2}{2\sigma^2}}$	$\frac{1}{2}\left[1 + \operatorname{erf}\left(\frac{\log(t) - \mu}{\sigma\sqrt{2}}\right)\right]$	$\mu \in \mathbb{R}, \sigma > 0$
Weibull	$rac{k}{\lambda}\left(rac{t}{\lambda} ight)^{k-1}e^{-(t/\lambda)^k}$	$1 - e^{-(t/\lambda)^k}$	$k,\lambda>0$
Type III	$\frac{\alpha\beta}{t}\left(\frac{t}{\gamma}\right)^{-\alpha}\left(1+\left(\frac{t}{\gamma}\right)^{-\alpha}\right)^{-\beta-1}$	$\left(1+\left(\frac{t}{\gamma}\right)^{-lpha}\right)^{-eta}$	$\alpha>1,\beta,\gamma>0$
Type X	$rac{2lpha t}{\gamma^2}e^{-\left(rac{t}{\gamma} ight)^2}\left(1\!-\!e^{-\left(rac{t}{\gamma} ight)^2} ight)^{lpha-1}$	$\left(1-e^{-\left(rac{t}{\gamma} ight)^2} ight)^{lpha}$	$\alpha,\gamma>0$
Type XII	$\frac{\alpha(\beta-1)}{\gamma}\left(1+\left(\frac{t}{\gamma}\right)^{\alpha}\right)^{-\beta}\left(\frac{t}{\gamma}\right)^{\alpha-1}$	$1 - \left(1 + \left(rac{t}{\gamma} ight)^{lpha} ight)^{1-eta}$	$\alpha,\beta,\gamma>0$
Derived	$rac{(rac{t}{eta}\!+\!lpha)igg(rac{T}{t}igg)^lpha e^{(T-t)/eta}}{tig(1\!+\!ig(rac{T}{t}ig)^lpha e^{(T-t)/eta}ig)^2}$	$\frac{1}{1+\left(rac{T}{t} ight)^{lpha}e^{-(t-T)/eta}}$	$\alpha,\beta,T>0$

Model comparison

We fit each type of Burr distribution to the data, and assess all the models in terms of 230 their goodness of fit in comparison to the more widely used gamma distribution. There 231 are various criteria that penalise models to varying degrees and judge models from 232 different perspectives, such as from an information theory view-point or an expected 233 loss view in decision theory. The most commonly used methods for model selection are 234 the Akaike information criterion (AIC) and Bayesian information criterion (BIC). The 235 AIC and BIC share a similarity in that the aim of a good model is to minimize their 236 score. Generally, AIC puts more emphasis on good model prediction, whereas BIC 237 favours model parsimony [25]. Because our goal is good model prediction, the AIC will 238 be used in deciding desirable model fits. 239

> By defining p as the number of parameters in the model and $\ell(X)$ as the log 240 likelihood of that model given the data X, the method to calculate the AIC is given as 241 follows: 242

$$AIC = -2\ell + 2p.$$
(5)

Additionally, we consider the difference between AIC values and the minimum AIC, [26] 243 defined this difference as $\Delta_i(AIC) = AIC_i - min(AIC)$, which is then used to calculate 244 the Akaike weights [26]: 245

$$w_i = \frac{e^{-\Delta_i (AIC)/2}}{\sum_j e^{-\Delta_j (AIC)/2}}.$$
(6)

When fitting models to data to compare the validity of a Burr distributed model over 246 the gamma distributed model, the weights w_i can be interpreted as the probability that 247 model i is the best model, given the data and set of models being considered [26]. 248 Furthermore, the ratio w_i/w_G , where w_i is the weight for the i^{th} model and w_G is the 249 weight of the gamma distributed model, can be interpreted as how much more likely 250 model i is the best fitting model compared to the gamma model. Alternatively, we also 251 derive the normalized probability that the i^{th} model is preferable to the gamma model, 252 given by $w_i/(w_i + w_G)$. 253

The final method of comparison considered is the Bayes factor. The maximum 254 likelihood estimates that we obtain in analysis can be considered maximum a posteriori 255 estimates with a uniform prior and are used in this context for conducting the Bayes 256 factor calculations. The ratio of likelihoods of two models determines whether there is 257 enough evidence to prefer one model to another. Let ℓ_A and ℓ_B be the likelihood of two 258 models, A and B respectively. We calculate the value 259

$$\log_{10}\left(\frac{\ell_A}{\ell_B}\right)$$

which is used for comparison between models. Based on [27], if this value is in the range $_{260}$ (0,0.5), there is little evidence that model A outperforms model B, (0.5, 1) gives $_{261}$ substantial evidence that model A outperforms model B, (1,1.5) gives strong evidence $_{262}$ that model A outperforms model B and the larger the value, the stronger the evidence $_{263}$

> that model A outperforms model B. This method shall be used to compare each of the Burr distributions separately with the gamma model. 265

Incubation-period data

To test these models, we employ incubation-period data from an outbreak of Legionnaires' disease in Melbourne in April 2000 [18]. The data for the Melbourne outbreak contains the number of days taken for each Legionnaires' disease case to develop symptoms from their exposure date, and several potential distributions for fitting the data have been compared [4]. The results indicated that the gamma distribution provided the best fit [4] out of their proposed models.

Further, we gather incubation-period data for anthrax, campylobacteriosis and 273 salmonellosis for analysis. The anthrax outbreak in 1979 contains data for the known 274 incubation-periods of patients [28]. A literature review has been conducted analysing 275 different salmonellosis studies that contain full data of the incubation periods [29]. 276 Awofisayo-Okuyelu et al. [29] noticed that the incubation periods varied between 277 studies. They grouped studies into subsets using a clustering process, in which the 278 grouped studies did not have any statistically significant difference in their 279 incubation-period data. Similarly, Awofisayo-Okuyelu et al. [30] conducted a review for 280 campylobacteriosis in which the incubation periods varied between studies, and they 281 combined datasets which were not statistically significantly different using a clustering 282 process similar to [29]. We provide an Excel sheet of the incubation-period data for 283 these other diseases in S4 Data in the Supplementary Material. 284

The data gathered for these diseases share a similarity with the Legionnaires' disease ²²⁶⁵ data, in that the data contains the integer number of days taken for each case to develop ²²⁶⁶ symptoms. The fact the data for all of these diseases contains integer days implies that ²²⁷⁷ each case takes an exact multiple of 24 hours from infection to the appearance of ²²⁸⁶ symptoms, which is not realistic. If we assume that the dates of infection and symptom ²²⁹⁷ onset are accurate, then we know the date of these events, but the specific times on the ²²⁹⁶ given days are unknown. We are dealing with doubly censored data. ²²⁹⁷

267

268

269

270

271

Results

Now that we have developed the Burr distribution as an incubation-period model based	29
upon biological justifications, the next step is to fit these models to the	29
incubation-period data of various diseases. We begin by fitting the incubation-period	29
models to the Legionnaires' disease data, to draw comparisons between the models'	29
performance. Next, we conduct the same analysis on other diseases such as anthrax,	29
campylobacteriosis and salmonellosis. Finally, we conduct a simulation in which	29
incubation-period data is fabricated. We compare the results from fitting the	29
incubation-period models to this data, as we compare the parameter estimates obtained	30
from fitting the gamma and derived Burr distributions to this data in an attempt to	30
assess the relationship between these parameters.	30

Analysis of the Melbourne data

The gamma distribution is currently most frequently used to model Legionnaires' ³⁰⁴ disease incubation periods [4], thus we produce models using a gamma distributed ³⁰⁵ incubation period, as well as a Burr distributed incubation period, to allow for ³⁰⁶ comparison between the two. Models are fitted using both the continuous and doubly ³⁰⁷ interval-censored models to offer comparison between the two methods. ³⁰⁸

This section begins by providing the results from fitting the incubation-period 309 models to the data (Table 2). Comparisons are drawn both between the 310 incubation-period models, as well as between model-fitting approaches and the effect 311 that has on our understanding of Legionnaires' disease incubation periods. We provide 312 analysis of the moments of these Legionnaires' disease incubation-period models in S1 313 Appendix in the Supplementary Material. Further, in this appendix we provide visual 314 comparison of the accumulated hazard of these models for large time, to examine their 315 ability to accurately display a Markovian property of long incubation periods. The 316 analysis and production of plots was conducted on R, with the code provided in S3 317 Code in the Supplementary Material. 318

Table 2. Results from fitting the gamma and four Burr distribution models to the319Melbourne incubation-period data using both the continuous and DI likelihood fitting320methods.321

292

Method	Analysis			Distribution		
1	I	Gamma	Burr III	Burr X	Burr XII	Derived
		$\alpha = 4.963$	$\alpha = 5.664$	$\alpha = 1.525$	$\alpha = 2.955$	$\alpha = 1.725$
	Darameter	(0.636)	(0.970)	(0.203)	(0.366)	(0.751)
	estimates	$\beta = 1.275$	$\beta = 0.444$	$\gamma = 6.054$	$\beta = 4.451$	$\beta = 2.738$
	(s.e)	(0.171)	(0.126)	(0.335)	(2.309)	(0.989)
	~		$\gamma = 7.690$		γ =10.031	T = 6.050
Continuous			(0.642)		(3.131)	(0.254)
	ML	-272.66	-270.92	-271.81	-271.15	-270.84
	AIC	549.32	547.83	547.62	548.29	547.67
	ω/ω_G	, , ,	2.106	2.340	1.674	2.282
	$\omega/(\omega + \omega_G)$	I	0.678	0.701	0.626	0.695
	BF	I	0.756	0.369	0.656	0.790
		$\alpha = 3.479$	$\alpha = 5.475$	$\alpha = 1.065$	$\alpha = 2.249$	$\alpha = 0.880$
	Parameter	(0.228)	(1.048)	(0.020)	(0.083)	(0.320)
	estimates	$\beta = 0.653$	$\beta = 0.334$	$\gamma = 5.848$	$\beta = 8.643$	β =2.110
	(s.e)	(0.00)	(0.009)	(0.134)	(98.094)	(0.315)
	~		γ =7.229		γ =14.194	T = 5.075
DI			(0.415)		(105.311)	(0.067)
	ML	-274.33	-271.42	-272.59	-272.27	-270.75
	AIC	552.66	548.84	549.18	550.54	547.50
	m/m_G	1	6.753	5.697	2.886	13.197
	$m/(m + m_G)$	I	0.871	0.851	0.743	0.930
	BF	I	1.264	0.756	0.895	1.555

When fitting using the continuous maximum likelihood method, types III, X, XII and the derived Burr perform better than the gamma regardless of which scoring

322

> criterion is used. Because type X is a two-parameter distribution, the fact that its 324 maximized log-likelihood is higher than gamma's automatically means that its 325 minimized AIC will be lower. Types III, XII and the derived Burr perform better than 326 gamma depending on how harshly they are penalized for their extra parameter. Based 327 on AIC, our ideal information criterion for model selection, these perform better than 328 the gamma distribution. On the whole, all Burr distributions perform better than the 329 gamma distribution. From considering the Akaike weights ratio w/w_G , the derived 330 Burr, type III, and type X are at least two times as likely to be a better-performing 331 model than the gamma distributed model. Additionally, each Burr model provides at 332 least a 62% chance of being a better fitting model than the gamma distributed model, 333 with the derived Burr model being 70% more likely to be better than the gamma model. 334 Looking at the Bayes factor, there is no substantial evidence to favour type X over the 335 gamma. However, this criterion gives substantial evidence that both types III, XII as 336 well as the derived Burr are all favourable over the gamma distribution. 337

> Next, when fitting using doubly interval-censoring methods, type X again 338 outperforms the gamma distribution. Types III, XII and the derived Burr perform 339 better than the gamma model, based on AIC, even with one extra parameter. When 340 considering the Akaike weights, all the Burr distributed models perform much better 341 than the gamma distribution, with the derived Burr being over 13 times more likely to 342 be the better-fitting model. Additionally, when considering $w/(w+w_G)$, all Burr 343 models are more likely to be perform better than the gamma distribution, with the 344 derived Burr being 93% likely. Finally, the Bayes factor for types X and XII both show 345 substantial evidence of a better fit than the gamma distribution. Further, the Bayes 346 factor for type III and the derived Burr both show strong evidence of a better fit than 347 the gamma model. 348

> The same conclusions are drawn regardless of maximum likelihood fitting method; ³⁴⁹ all the distributions provide a better fit than the gamma distribution. Results from ³⁵⁰ using the DI methods agrees with the continuous likelihood method in that β_{XII} and ³⁵¹ γ_{XII} in the Burr type XII model have large standard errors, indicating that they are ³⁵² not important in the model fitting procedure. ³⁵³

> When fitted using continuous maximum likelihood methods, all Burr distributions ³⁵⁴ considered offer a similar curve when plotted, as expected, but do vary slightly as to the ³⁵⁵

> model value or the value of the p.d.f. at the mode (Fig. 2). The Weibull distribution ³⁵⁶ provides a similar modal value for the incubation period, but is more variable than the ³⁵⁷ Burr models. The gamma distribution provides a slightly lower modal value than the ³⁵⁸ Burr models. The log-normal model provides a noticeably different curve to the Burr ³⁵⁹ models and provides a much lower modal incubation period, with a lighter left tail and ³⁶⁰ heavier right tail than all the other distributions. ³⁶¹

Fig 2. A plot of the Melbourne case data with the four fitted Burr distributions included, which offer a visual representation of the incubation-period distributions trialled.



Melbourne Data with Model Fits

The mean of each fitted distribution along with a bootstrapped 95% confidence ³⁶⁵ interval is calculated under both the continuous method and the doubly ³⁶⁶ interval-censored method to identify any differences across distributions and across ³⁶⁷ methods, and is provided in Table 1 of S2 Figure in the Supplementary Material. A ³⁶⁸ common theme exists, which is that, for each distribution, the mean for the doubly ³⁶⁹ interval-censored model is approximately a day less than the continuous model (5.3 days ³⁷⁰ compared to 6.3 days), with the confidence intervals for each model having no overlap ³⁷¹

362

363

> across all the distributions. These results are statistically significant and provide 372 support for using a doubly interval-censored model to more accurately represent the 373 incubation period of Legionnaires' disease. 374

> For all of the distributions, the density under the doubly interval-censored approach ³⁷⁵ is shifted more towards the left, indicating that the incubation period is shorter than ³⁷⁶ when just taking the incubation period as exact integer days (Fig. 3). Indeed, the ³⁷⁷ doubly interval-censored methods account for a potential delay between exposure time ³⁷⁸ and infection as well as a delay between symptoms starting to develop and the person ³⁷⁹ reporting the symptoms, whereas the continuous model does not account for either ³⁸⁰ delay, resulting in longer times for the incubation periods. ³⁸¹

> Fig 3. Plots of the Melbourne data with the continuous model fits in red and the doubly interval-censored model fit as a step function in yellow. Each step of the function is a horizontal line from $t \in (a, b]$ where $a = \lfloor t \rfloor$ and $b = \lceil t \rceil$.



Application to other diseases

To further check the validity of the Burr distribution, we fit the doubly 386 interval-censored models to data of the incubation periods for different diseases: 387 anthrax [28], campylobacteriosis [30] and salmonellosis [29]. Figures of resulting model 388 fits provided in S2 Figure in the Supplementary Material, along with the obtained 389 parameter estimates and standard errors of these estimates contained in Table 1 of S2 390 Figure in the Supplementary Material. We use both the continuous and the doubly 391 interval-censored methods to fit the gamma and the Burr distributions, to compare 392 which model provides a better fit (Table 3). 393

Table 3. Comparing Burr and gamma models on anthrax, salmonellosis and394campylobacteriosis datasets. For this table: Y represents that the given model395outperforms the gamma distribution, N represents that the given model does not396outperform the gamma distribution and H represents that the given model outperforms397the gamma distribution based on maximum likelihood, but not on AIC.398

			Distri	bution	
Disease	Method	Burr III	Burr X	Burr XII	Derived
Anthrax	DI	Y	N	Н	Н
	Continuous	Y	N	Y	Η
Salmonellosis	DI	HYYY	YYNN	YYYY	HYYY
	Continuous	NYYN	YYNN	YYYY	HYYY
Campylobacteriosis	DI	YNNYY	NNYNY	HNNYY	YHNYY
	Continuous	YYNYY	NNNNY	YYNYY	YYNYH

Burr types III and X offer mixed results across datasets and do not consistently ³⁹⁹ outperform the gamma distribution. Apart from the third campylobacteriosis dataset, ⁴⁰⁰ both the derived Burr and type XII Burr models consistently outperform the gamma ⁴⁰¹ distribution. When comparing optimal fits across datasets, the derived Burr appears to ⁴⁰² be the most optimal out of these choices of models. ⁴⁰³

We note that there is no clear pattern between any of the fitted α_D and β_D 404 parameter estimates and the performance of the derived Burr distribution. Additionally, 405 there is no clear pattern from the anthrax, campylobacteriosis and salmonellosis 406 datasets as to whether the estimate of the median, T_D , relates to the performance of the 407 derived Burr model. However, the lack of sensitivity for T_D is logical as T_D solely scales 408 the distribution about the median, and the ability of the derived Burr distribution to fit 409 well to incubation period data will depend more on the tails in the curve and around 410 the median, as opposed to the median itself. 411

We can draw conclusions on which scenarios the derived Burr distribution will⁴¹² outperform the gamma distribution based on plots provided in Figure 1 of S2 Figure of⁴¹³ the Supplementary Material. The third campylobacteriosis dataset was the only dataset⁴¹⁴ in which the derived Burr did not outperform the gamma distribution based on either⁴¹⁵ maximized likelihood or on AIC. This dataset is unique in that the incubation period⁴¹⁶ ranges from one to five days. As a result, the effect of the censoring bias will be much⁴¹⁷ larger, due to the fact that this incubation period is much shorter. Therefore, this is not⁴¹⁸

an ideal dataset to use to assess model performance.

Next, we consider the datasets in which the derived Burr outperformed the gamma 420 distribution based on maximized likelihood but not on AIC, regardless of model fitting 421 procedure. The anthrax dataset has a high density after the mode and does not tail off, 422 and the probability distribution of the first salmonellosis dataset does not have a clearly 423 defined mode and is negatively skewed. The derived Burr distribution offers close 424 results to the gamma distribution when it comes to modelling incubation periods 425 without a clear mode or tail off in probability of illness, but is a better-performing 426 distribution when this structure is clearer defined. 427

Finally, fitting to the second and fifth campylobacteriosis datasets resulted in the 428 derived Burr outperforming the gamma on maximized likelihood but not on AIC. The 429 incubation period for these datasets is relatively small, meaning that the bias from the 430 censoring issue is large when fitting models to these datasets. The campylobacteriosis 431 datasets that resulted in the derived Burr distribution outperforming the gamma 432 distribution were the ones in which the modal time was clearly defined and not a wide 433 range of times at the peak of the distribution. This further supports the hypothesis that 434 the derived Burr becomes more preferable when either the mode is more apparent, or 435 the range of incubation periods in the datasets is not too short that the censoring 436 becomes a larger issue. 437

Results of model-fitting to simulated data

We now further assess the validity of the Burr distributions by comparing their fits, along with those of the gamma distribution, to fabricated data. Specifically, we aim to analyse how the parameter estimates of the gamma distribution relate to the parameter estimates of the derived Burr distribution for different datasets, to gain a further understanding of how the derived Burr parameters can be interpreted. 449

Initially, we generate a sample of size 1000 from a gamma distribution with given shape α_{Γ} and mean μ_{Γ} (scale $\beta_{\Gamma} = \mu_{\Gamma}/\alpha_{\Gamma}$). Then the derived Burr parameter estimates are obtained from fitting to this dataset by continuous maximum likelihood, so that analysis can be conducted on the effect that varying $\alpha_{\Gamma} \in (0, 5)$ or $\mu_{\Gamma} \in (1, 20)$ has on these estimates. A heatmap is produced to visualise this effect (Fig. 4).

419

> Fig 4. Heatmap of the results from the third simulation. The derived Burr 449 distribution is fitted to data generated from the gamma distribution with parameters α_{Γ} 450 and μ_{Γ} , with the obtained derived Burr parameter estimates plotted. 451



(a) Corresponding α_D estimate from data sampled from the gamma distribution.

(b) Corresponding β_D estimate from data sampled from the gamma distribution.



(c) Corresponding T_D estimate from data sampled from the gamma distribution.

Parallels exist between the interpretations of α_{Γ} and α_D . Increasing α_{Γ} results in a larger discrepancy between the gamma distribution and the exponential distribution. Thus, α_{Γ} limits quickly the distribution becomes Markovian over time. Therefore, a positive correlation between α_{Γ} and α_D is expected (Fig. 4a). The results indicate that μ_{Γ} does not have an effect on the rate at which the gamma distribution becomes 450

Markovian.

Similarly, parallels exist between the interpretations of β_{Γ} and β_{D} . The hazard rate 458 for the gamma distribution tends to $1/\beta_{\Gamma}$ as $t \to \infty$. Hence, $1/\beta_{\Gamma}$ as the eventual 459 Markovian rate of symptom onset for this distribution. Thus, a positive correlation 460 between β_{Γ} and β_{D} is logical (Fig. 4b). Therefore, the effect that varying either μ_{Γ} or 461 α_{Γ} in $\mu_{\Gamma} = \alpha_{\Gamma}\beta_{\Gamma}$ has on β_{Γ} is likely to inform the effect that varying either μ_{Γ} or α_{Γ} 462 has on β_{D} .

Finally, a positive correlation between μ_{Γ} and T_D is expected, as they both represent a form of average. For large α_{Γ} , the gamma distribution becomes symmetric, hence $T_D \rightarrow \mu_{\Gamma}$. However, the correlation becomes less linear as α_{Γ} decreases. In this case, $\mu_{\Gamma} - T_D$ and equivalently the skewness (defined by $1/\sqrt{\alpha_{\Gamma}}$ for the gamma distribution) increases (Fig. 4c).

Discussion

This paper brings attention to and provides solutions to two distinct issues involved in modelling incubation periods of diseases. First, we derive a new model for delays between key events in an individual's infection history, specifically the incubation period, that has justifiable mechanistic reasons for its validity. Second, we adapt methods for using incubation-period data, that is given as an integer number of days and has issues with bias, to fit models.

We considered the probability of an individual changing from the 476 not-vet-symptomatic population to symptomatic for deriving our mathematical model. 477 This approach led to obtaining a differential equation equivalent to the equation 478 defining the exponential c.d.f. with a time-varying rate parameter. We then extended 479 the model with further assumptions to further develop the differential equation 480 describing the incubation period. We considered the likely event that the probability of 481 symptom onset after infection is proportional to the bacterial load before saturating at 482 some large load, as well as considering that bacterial population is expected to grow 483 exponentially. Further, we derived a specific distribution within the Burr family that 484 satisfies a Markovian property of long incubation periods. Other trial functions for G(t)485 may offer results at least as good as this new model, and some in-host dynamics which 486

457

affect the rate of symptom onset in populations could be considered for specific diseases 487 to provide even more optimal forms of the Burr model. 488

Further, by considering models that account for the fact that both the infection and 489 symptom onset times are not exactly known (doubly interval-censored models), we have 490 obtained expected incubation periods that are statistically significantly less than 491 previously thought (by a whole day) using standard statistical distributions with 492 incubation-period data. The mathematical derivation of the new model and 493 implementation of this model with doubly interval-censored methods address both these 494 problems, as we arrive at a mechanistic model for incubation periods. Our model has 495 few restrictions on which diseases it can be applied to, as well as highlights the need to 496 account for the censored nature of the data due to statistically significant difference 107 recorded in calculated incubation periods when incorporating the DI methods into the 498 model. 499

Our argument leading to the Burr family of distributions provides a valid 500 incubation-period model, but does not consider factors such as an individual's age, 501 levels of immune response, susceptibility, doses received or the disease-specific in-host 502 dynamics at play which determine if and when an individual becomes ill with an 503 infection. For example, frailty may mean faster onset of symptoms, as may higher doses. 504 This flexibility means that the exact disease-specific in-host dynamics are not considered, 505 and to derive a model considering the biological processes at play with a given disease, a 506 different model would have to be derived based on the details of those dynamics. 507

In Figure 1 of S1 Appendix in the Supplementary Material, we noticed that all Burr 508 distributions valid over $(0, \infty)$, apart from type X, exhibited a Markovian property for 509 long incubation periods. Consequently, we compared the results of using this model to 510 the other Burr distributions to judge the validity of the Markovian assumption. The 511 type X provides successful results outperforming the gamma in nearly all of the analysis 512 (we obtain mixed results when fitting to other diseases). However, when compared to all 513 of the other Burr distributions, type X performed the worst when fitting to the original 514 Legionnaires' disease dataset, the original Legionnaires' disease dataset with doubly 515 interval-censored methods and the other diseases with doubly interval-censored methods. 516 Further, type X visually fits the worst to the Legionnaires' disease data (Fig. 2). These 517 consistent results support our Markovian assumption for long incubation periods, and 518 indicate that, although non-Markovian Burr distributions provide better-performing 519 models to the widely used gamma model, the Markovian Burr models provide a further 520 improvement in terms of distributional modelling. 521

Our proposed model can be applied in a number of ways in epidemiology and 522 infectious disease modelling. For example, a common area of research for 523 person-to-person transmissible diseases, such as COVID-19, is to develop 524 compartmental and time-since-infection models where the infectivity of inflicted 525 individuals infecting susceptible individuals in a population is modelled. Typically an 526 exponential distribution from the point in time at which they are infected is used for 527 modelling. However this approach can be improved upon by considering that an 528 individual will have an incubation period before they are infectious to others. This 529 improvement can be achieved by taking the convolution of the Burr incubation-period 530 model and the exponential infectious period to gain a more reliable model for infectivity, 531 improving the overall reliability of these models. In this work, we have limited to time 532 delay distributions with range of times that are strictly positive, as must be the case 533 with the incubation period. Some epidemiological distributions, such as generation time, 534 are not bound by this constraint and so care would be needed in application. 535

Furthermore, we may consider diseases that do not have a person-to-person⁵³⁶ transmissible property such as Legionnaires' disease, which has been the focus of this⁵³⁷ research. Researchers typically track backwards from symptom onset date to predict⁵³⁸ source location of the infection for elimination and public safety. A more reliable model⁵³⁹ such as the model developed here can provide more accurate results when predicting⁵⁴⁰ locations or causes of Legionnaires' disease cases, which will result in reduction of⁵⁴¹ bacterial hot-spots and consequently cases of this disease.⁵⁴²

This paper provides a flexible model that can reliably fit incubation-period data to a ⁵⁴³ level that is not currently seen in the literature and is valid for a wide range of diseases. ⁵⁴⁴ We have validated this with our results indicating that using the Burr family of ⁵⁴⁵ distributions as a model for incubation periods are better performing than currently ⁵⁴⁶ accepted models [4] for the diseases that we have analysed. ⁵⁴⁷

Acknowledgements

NJ acknowledges support from the Engineering and Physical Sciences Research Council	549
(EPSRC) and Mathematics and Data in Scientific and Industrial Modelling (MADSIM)	550
at the University of Manchester for funding of their studentship.	551

IH was supported by the JUNIPER modelling consortium (grant MR/V038613/1) 552 the National Core Study on Transmission (PROTECT) and by the UKRI Impact 553 Acceleration Account (IAA 386). NJ and IH also acknowledge the UK Health Security 554 Agency (UKHSA) for honorary contracts and funding (for IH). The views expressed are 555 those of the author(s) and not necessarily those of the Department of Health or UKHSA. 556

References

- Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious disease outbreak controllable. Proceedings of the National Academy of Sciences. 2004;101(16):6146-6151.
- Klinkenberg D, Fraser C, Heesterbeek H. The effectiveness of contact tracing in emerging epidemics. PLoS ONE 1(1): e12. https://doi.org/10.1371/journal.pone.0000012
- Wood RM, Egan JR, Hall IM. A dose and time response markov model for the in-host dynamics of infection with intra-cellular bacteria following inhalation: With application tofrancisella tularensis. Journal of The Royal Society Interface. 2014;11(95):20140119.
- Egan JR, Hall IM, Lemon DJ, Leach S. Modeling legionnaires' disease outbreaks. Epidemiology. 2011;22(2):188–198.
- Ward T, Glaser A, Overton C, Carpenter B, Gent N, Seale. Replacement dynamics and the pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2. Epidemiology and Infection, 151. Dec 2022. doi: 10.1017/s0950268822001935.

- Ward T, Christie R, Paton R, Cumming F, Overton C. Transmission dynamics of monkeypox in the United Kingdom: contact tracing study. BMJ, Nov 2022. doi: 10.1136/bmj-2022-073153.
- Keeling MJ, Rohani P. Modeling infectious diseases: In humans and animals. Princeton University Press; 2011.
- Braeye T, Echahidi F, Meghraoui A, Laisnez V, Hens N. Short-term associations between Legionnaires' disease incidence and meteorological variables in Belgium, 2011-2019. Epidemiology and Infection. 2020 04;148:e150.
- De Giglio O, Fasano F, Diella G, Lopuzzo M, Napoli C, Apollonio F, et al. Legionella and legionellosis in touristic- recreational facilities: Influence of climate factors and geostatistical analysis in Southern Italy (2001-2017). Environmental Research. 2019 11;178:108721.
- Dunn CE, Rowlingson B, Bhopal RS, Diggle P. Meteorological conditions and incidence of Legionnaires' disease in Glasgow, Scotland: application of statistical modelling. Epidemiology and Infection. 2013 Apr;141(4):687-96.
- Fisman DN, Lim S, Wellenius GA, Johnson C, Britz P, Gaskins M, et al. It's not the heat, it's the humidity: Wet weather increases legionellosis risk in the Greater Philadelphia metropolitan area. The Journal of Infectious Diseases. 2005;192(12):2066–2073.
- Gleason JA, Kratz NR, Greeley RD, Fagliano JA. Under the weather: legionellosis and meteorological factors. Ecohealth. 2016 06;13(2):293-302.
- Halsby KD, Joseph CA, Lee JV, Wilkinson P. The relationship between meteorological variables and sporadic cases of Legionnaires' disease in residents of England and Wales. Epidemiology and Infection. 2014 Nov;142(11):2352-9.
- Ricketts KD, Charlett A, Gelb D, Lane C, Lee JV, Joseph CA. Weather patterns and Legionnaires' disease: a meteorological study. Epidemiology and Infection. 2009 Jul;137(7):1003-12.

- Karagiannis I, Brandsema P, Van Der Sande M. Warm, wet weather associated with increased Legionnaires' disease incidence in the Netherlands. Epidemiology and Infection. 2009 Feb;137(2):181-7.
- 16. Beauté J, Sandin S, Uldum SA, Rota MC, Brandsema P, Giesecke J, et al. Short-term effects of atmospheric pressure, temperature, and rainfall on notification rate of community-acquired legionnaires' disease in four European countries. Epidemiology and Infection. 2016;144(16):3483–3493.
- 17. Brandsema PS, Euser SM, Karagiannis I, Den Boer JW, Van Der Hoek W. Summer increase of Legionnaires' disease 2010 in The Netherlands associated with weather conditions and implications for source finding. Epidemiology and Infection. 2014 Nov:142(11):2360-71.
- Greig JE, Carnie JA, Tallis GF, Zwolak B, Hart WG, Guest CS, et al. An outbreak of legionnaires' disease at the Melbourne aquarium, April 2000: Investigation and case–control studies. Medical Journal of Australia. 2004;180(11):566–572.
- Reich NG, Lessler J, Cummings DA, Brookmeyer R. Estimating incubation period distributions with coarse data. Statistics in Medicine. 2009;28(22):2769–2784.
- Chakraborty S. Generating discrete analogues of continuous probability distributions- A survey of methods and constructions. Journal of Statistical Distributions and Applications. 2015;2(1).
- 21. Hadjichrysanthou C, Cauët E, Lawrence E, Vegvari C, de Wolf F, Anderson RM. Understanding the within-host dynamics of influenza A virus: From theory to clinical implications. Journal of The Royal Society Interface. 2016;13(119):20160289.
- Heppell CW, Egan JR, Hall I. A human time dose response model for Q fever. Epidemics. 2017;21:30–38.

- Hakim AR, Fithriani I, Novita M. Properties of Burr distribution and its application to heavy-tailed survival time data. Journal of Physics: Conference Series. 2021;1725(1):012016.
- van den Broek J, Heesterbeek H. Nonhomogeneous birth and death models for epidemic outbreak data. Biostatistics. 2006;8(2):453–467.
- Dziak JJ, Coffman DL, Lanza ST, Li R, Jermiin LS. Sensitivity and specificity of information criteria. Briefings in Bioinformatics. 2019;21(2):553–565.
- Wagenmakers EJ, Farrell S. AIC model selection using Akaike weights. Psychonomic Bulletin and Review. 2004;11(1):192–196.
- 27. Jeffreys H. Theory of probability. Oxford: Clarendon. (1961).
- Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, Shelokov A, et al. The Sverdlovsk anthrax outbreak of 1979. Science. 1994;266(5188):1202–1208.
- 29. Awofisayo-Okuyelu A, McCarthy N, Mgbakor I, Hall I. Incubation period of typhoidal salmonellosis: A systematic review and meta-analysis of outbreaks and experimental studies occurring over the last century. BMC Infectious Diseases. 2018;18(1).
- Awofisayo-Okuyelu A, Hall I, Adak G, Hawker JI, Abbott S, McCarthy N. A systematic review and meta-analysis on the incubation period of Campylobacteriosis. Epidemiology and Infection. 2017;145(11):2241–2253.

Supporting information

S1 Appendix. Moments calculations for derived Burr and scaled type XII distributions. Further Legionnaires' disease modelling analysis of mean incubation period and cumulative hazards.

S2 Figure. Figures and parameter estimates of anthrax, campylobacteriosis and salmonellosis datasets with model fits for gamma, burr types III, X, XII and the derived Burr based on the original and doubly interval-censored methods.

S3 Code. R code for conducting analysis and producing plots in this research.

https://github.com/NyallJamieson/Burr-Incubation-Period

S4 Data. Incubation period data for the diseases analysed in this research.